Mouse monoclonal antibodies against the receptor binding domain of SARS-CoV-2 spike protein
Updated time: 2020-07-08 20:56:09
Mouse monoclonal antibodies against the receptor binding domain of SARS-CoV-2 spike protein
Abstract
We generated mouse B cell hybridomas to produce specific monoclonal antibodies recognizing SARS-CoV-2 spike protein. Two types of antigens were used. One is fusion protein containing receptor binding domain (RBD) of SARS-CoV-2 spike proteins. The other is two synthetic peptides covering the receptor binding motif (RBM) of SARS-CoV-2 spike proteins.
Technological Advantages
- High specificity
- High affinity
- Multiple different clones are available for various purposes
- Multiple applications

Figure1. ELISA to measure antibody-antigen interaction.
Docket Number
13A-1090527
Announcement Date
2020-06-08
IP Status
U.S. provisional case pending
Applications of Technology
- Basic research to explore the various properties of SARS-CoV-2, applicable in ELISA, immunoblotting, immunostaining and immunostaining.
- To develop SARS-CoV-2 rapid diagnosis kit.
- To develop SARS-CoV-2 therapeutic neutralization antibody.
Inventor
Yi-Ping Hsueh
Contact person
If you are interested in this technology, please fill in the information on the webpage under the manufacturer option (Request for Technology Licensing, Material Transfer, or Sponsored Research) on the website of this office

Mouse monoclonal antibodies against the receptor binding domain of SARS-CoV-2 spike protein